Residency · Residency · Cardiology

Ventricular Tachycardia: Mechanisms and Management

Classification

By Duration and Hemodynamic Impact

Non-sustained ventricular tachycardia is defined as three or more consecutive beats at a rate exceeding 100 beats per minute, lasting less than 30 seconds and self-terminating. Sustained ventricular tachycardia lasts 30 seconds or longer, or requires intervention such as cardioversion or antiarrhythmic drug administration due to hemodynamic compromise. Monomorphic VT is characterized by a uniform QRS morphology and consistent cycle length, implying an organized reentrant circuit or focal origin. Polymorphic VT exhibits changing QRS morphology and axis from beat to beat, indicating an unstable electrophysiologic substrate. When polymorphic VT occurs in the setting of a prolonged QT interval, it is classified as torsades de pointes.

By Mechanism

Reentrant VT is the most common mechanism in the setting of structural heart disease, driven by scar-related circuits with zones of slow conduction, critical isthmuses, and defined entrance and exit sites. Triggered activity involves delayed afterdepolarizations, which are seen in catecholaminergic states and digitalis toxicity, and early afterdepolarizations, which underlie torsades de pointes in long QT syndrome. Automaticity refers to abnormal automaticity in ischemic or diseased tissue, a classic example being accelerated idioventricular rhythm observed during myocardial reperfusion.

By Clinical Context

Ischemic VT is the most common sustained VT in adults and results from post-myocardial infarction scar-related reentry, where dense scar with viable myocyte channels creates slow conduction corridors. Non-ischemic VT encompasses a range of substrates including dilated cardiomyopathy with basal septal scar and endocardial or epicardial circuits, hypertrophic cardiomyopathy with septal fibrosis, arrhythmogenic right ventricular cardiomyopathy with fibrofatty replacement of the RV free wall, and cardiac sarcoidosis. Idiopathic VT occurs in structurally normal hearts and includes right ventricular outflow tract VT, fascicular VT, papillary muscle VT, and aortomitral continuity VT. Bundle branch reentrant VT occurs in large dilated hearts with His-Purkinje disease, utilizing a macro-reentrant circuit involving the right and left bundle branches.

Idiopathic Ventricular Tachycardia

RVOT VT

Right ventricular outflow tract VT is the most common idiopathic VT and presents with a left bundle branch block morphology and inferior axis, with positive deflections in leads II, III, and aVF and precordial transition at V3 to V4. The underlying mechanism is triggered activity mediated by cyclic AMP-dependent delayed afterdepolarizations, making it catecholamine-sensitive. Patients typically present with exercise-induced or repetitive monomorphic VT and frequent premature ventricular complexes of the same morphology. The prognosis is benign in the context of a structurally normal heart. Treatment options include beta-blockers, calcium channel blockers such as verapamil, and catheter ablation, which achieves success rates exceeding 95%. Flecainide is an additional pharmacologic option.

Left Fascicular VT (Belhassen/Idiopathic Left VT)

Left fascicular VT involves a reentrant circuit utilizing the left posterior fascicle and presents with a right bundle branch block morphology and left axis deviation, also known as superior axis. The QRS is relatively narrow for VT, typically measuring 120 to 140 milliseconds. A distinguishing feature is its sensitivity to verapamil, which differentiates it from scar-related VT. It occurs in young patients without structural heart disease and carries an excellent prognosis. Ablation targeting Purkinje potentials along the left posterior fascicle achieves success rates exceeding 90%.

Papillary Muscle VT

Papillary muscle VT originates from the anterolateral or posteromedial papillary muscle and frequently exhibits variable morphology due to the broad origin of the papillary muscle. Multiple morphologies are often present, and ablation can be technically challenging due to the unstable catheter position on the papillary muscle surface. The QRS may demonstrate either right or left bundle branch block morphology depending on whether the origin is the left or right ventricular papillary muscle.

Outflow Tract VT (Non-RVOT)

Left ventricular outflow tract VT presents with a left bundle branch block morphology and inferior axis but with earlier precordial transition at V1 to V2, distinguishing it from RVOT VT. Origins may include the aortic cusps, particularly the left and right coronary cusps, and the aortomitral continuity. Pulmonary artery VT originates above the pulmonic valve and shares the left bundle branch block inferior axis pattern but with later precordial transition than RVOT VT. Epicardial VT from the summit region may be inaccessible to endocardial ablation due to proximity to coronary arteries, and ablation may require a great cardiac vein or anterior interventricular vein approach.

<image> A 12-lead ECG morphology comparison of common idiopathic VT origins. Six panels showing the characteristic ECG pattern for each origin with a small cardiac diagram indicating the anatomical source. Panel 1: RVOT VT - LBBB inferior axis, transition V3-V4, heart diagram with star at RVOT. Panel 2: LVOT/Aortic cusp VT - LBBB inferior axis, early transition V1-V2, star at LCC/RCC junction. Panel 3: Left posterior fascicular VT - RBBB superior axis, relatively narrow QRS, star at left posterior fascicle. Panel 4: Left anterior fascicular VT - RBBB inferior axis (right axis deviation), star at left anterior fascicle. Panel 5: Papillary muscle VT (posteromedial) - RBBB with variable axis, star at posteromedial papillary muscle. Panel 6: Epicardial summit VT - broad QRS with pseudo-delta wave, delayed intrinsicoid deflection >85ms, MDI >0.55, star at LV summit region. Each ECG should show all 12 leads clearly with key morphologic features annotated with arrows. Use consistent color coding: blue for right-sided origins, red for left-sided, green for fascicular. </image>

Scar-Related VT

Substrate and Circuit

Post-myocardial infarction scar provides the substrate for the majority of clinically significant ventricular tachycardias. Dense scar, composed of regions devoid of viable myocytes that are unable to conduct electrical impulses, is surrounded by border zones containing surviving myocyte bundles interspersed with fibrosis. Slow conduction through these surviving channels within or around the scar enables the formation of reentrant circuits. The critical isthmus is a narrow channel of conducting tissue bounded by scar or anatomic barriers and represents the primary ablation target. The entrance site is where the wavefront enters the isthmus, and the exit site is where it emerges, producing the QRS morphology seen on the surface ECG. Patients often harbor multiple potential VT morphologies arising from the same scar substrate due to the presence of multiple circuits.

ECG Localization

A right bundle branch block morphology during VT suggests an exit site in the left ventricular septum or right ventricle, while a left bundle branch block morphology suggests an exit from the right ventricular free wall or left ventricle if the origin is right ventricular. Axis deviation provides additional localization: a superior axis points to an exit from the inferior wall, an inferior axis to exit from the anterior or superior wall, and a rightward axis to exit from the left ventricular lateral wall. A wider QRS suggests an epicardial or mid-myocardial exit, as the impulse conducts more slowly through working myocardium before reaching the Purkinje system. Positive precordial concordance indicates a basal exit, while negative concordance suggests an apical exit.

Cardiac MRI for VT Substrate Characterization

Late gadolinium enhancement on cardiac MRI identifies both core scar and border zone tissue, with the border zone mass correlating with VT inducibility and arrhythmic risk. High-resolution CMR can visualize channels of viable myocardium within scar, which can be correlated with VT circuits. Integration of CMR scar maps into electroanatomic mapping systems such as CARTO and EnSite enables image-guided VT ablation. Native T1 mapping identifies diffuse fibrosis even in the absence of late gadolinium enhancement.

Acute Management

Hemodynamically Unstable VT

Pulseless VT requires defibrillation with unsynchronized shocks per Advanced Cardiovascular Life Support protocols, along with CPR, epinephrine, and amiodarone 300 mg intravenous bolus followed by 150 mg. Unstable VT with a pulse warrants synchronized cardioversion at 100 to 200 joules biphasic. Following cardioversion, an intravenous amiodarone infusion at 1 mg/min for 6 hours followed by 0.5 mg/min for 18 hours should be initiated, and electrolytes should be corrected to maintain potassium above 4.0 mEq/L and magnesium above 2.0 mg/dL.

Hemodynamically Stable Monomorphic VT

Intravenous amiodarone, administered as 150 mg over 10 minutes with repeat doses as needed, is the most commonly used agent. However, intravenous procainamide at 10 to 17 mg/kg at a rate of 20 to 50 mg/min is preferred per the 2017 AHA/ACC/HRS guidelines, based on the PROCAMIO trial which demonstrated superiority of procainamide over amiodarone for hemodynamically stable wide complex tachycardia with fewer adverse events. Intravenous lidocaine, given as a 1 to 1.5 mg/kg bolus followed by a 1 to 4 mg/min infusion, is useful for ischemic VT and serves as a second-line agent. Verapamil must be strictly avoided unless confirmed idiopathic fascicular VT, as administration to patients with scar-related VT can cause fatal cardiovascular collapse.

Polymorphic VT

When the QT interval is prolonged, indicating torsades de pointes, management consists of intravenous magnesium 2 grams over 2 to 5 minutes, overdrive pacing using temporary transvenous pacing or isoproterenol to increase the heart rate to 100 to 120 beats per minute, correction of hypokalemia, and immediate discontinuation of all QT-prolonging drugs. When the QT interval is normal, polymorphic VT should be treated as ischemia-driven until proven otherwise, with urgent angiography and administration of beta-blockers along with an antiarrhythmic such as amiodarone or lidocaine.

Electrical Storm

Electrical storm is defined as three or more episodes of sustained VT or ventricular fibrillation within 24 hours. Acute management requires deep sedation with propofol and intubation, intravenous amiodarone, intravenous beta-blocker therapy with an esmolol drip at 50 to 200 mcg/kg/min, and consideration of stellate ganglion block or epidural anesthesia for sympatholysis. Mechanical circulatory support with Impella or VA-ECMO may be necessary if hemodynamic compromise persists despite medical therapy. Urgent catheter ablation should be considered if VT storm is refractory to medical therapy, as it can reduce recurrence in the acute setting. Thoracic epidural or bilateral stellate ganglion block is highly effective for refractory VT storm by interrupting sympathetic input to the heart.

Catheter Ablation for VT

Mapping Techniques

Activation mapping during VT identifies the exit site by locating the earliest endocardial activation, which precedes the QRS by 30 to 80 milliseconds. This approach requires a hemodynamically tolerable VT. Entrainment mapping involves pacing during VT at a cycle length 20 to 40 milliseconds shorter than the VT cycle length. A post-pacing interval minus tachycardia cycle length of less than 30 milliseconds at isthmus sites confirms proximity to the circuit, and concealed entrainment, where the paced QRS is identical to the VT QRS, identifies a critical isthmus site. Substrate mapping is performed during sinus rhythm using voltage mapping to identify low-voltage scar, channels of preserved voltage within dense scar, and pace mapping to match QRS morphology to the clinical VT at putative exit sites. Late and fractionated potentials serve as ablation targets. Abnormal electrograms are characterized by low voltage below 0.5 mV bipolar in the left ventricle and below 1.0 mV in the right ventricle, fractionated signals with multiple components, late potentials occurring after the QRS, and isolated diastolic potentials representing mid-diastolic signals during VT that indicate the isthmus.

Ablation Strategies

Focal ablation targets the critical isthmus or exit site and is most effective when VT is inducible and hemodynamically stable for mapping. Substrate-based ablation is employed for unmappable VT that is either hemodynamically unstable or non-inducible, and involves ablation of all abnormal electrograms in the scar, elimination of late potentials, and pace-map guided ablation. Homogenization represents the most aggressive approach, involving extensive ablation of the entire scar border zone with higher acute success but greater lesion burden.

Ischemic VT is typically endocardial due to the subendocardial distribution of myocardial infarction scar, while non-ischemic VT from dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, sarcoidosis, and Chagas disease often requires a combined endocardial and epicardial approach. Epicardial access is obtained through subxiphoid percutaneous pericardial puncture using the Sosa technique with fluoroscopic guidance. Risks include right ventricular puncture, coronary artery injury, and phrenic nerve palsy.

Outcomes

Post-MI VT ablation achieves 60 to 70% freedom from recurrent VT at 1 to 2 years. The VANISH trial demonstrated that catheter ablation is superior to escalation of antiarrhythmic drug therapy for VT recurrence in patients with ischemic cardiomyopathy and an ICD. Non-ischemic VT ablation has variable success rates of 50 to 70%, reflecting the frequent involvement of epicardial substrate and the potential need for multiple procedures. The BERLIN VT study and PARTITA trial support early ablation for VT in patients with ICDs.

Complications

Stroke or transient ischemic attack occurs in 1 to 2% of cases due to thrombus formation on catheters in the left ventricle, necessitating systemic heparinization during the procedure. Cardiac tamponade occurs in 1 to 2%, with higher rates associated with epicardial access, and is managed with pericardiocentesis and rarely surgical repair. AV block is a risk with septal ablation near the His bundle. Coronary artery injury is a risk with epicardial ablation near coronary arteries, and a minimum distance of 5 mm from coronary arteries should be maintained, with coronary angiography performed during epicardial ablation to map the coronary course. Vascular complications occur in 2 to 3%.

<image> An electroanatomic voltage map of the left ventricle in a patient with prior anteroseptal MI and VT. Show two views: (1) Left anterior oblique (LAO) view of the LV endocardium as a 3D shell with voltage color map. Dense scar (< 0.5 mV) shown in red/gray in the anteroseptal region extending from the apex to the mid-cavity. Border zone (0.5-1.5 mV) shown in yellow/green surrounding the scar. Normal voltage (> 1.5 mV) shown in purple. Within the dense scar, two narrow channels of preserved voltage (shown as green/yellow streaks) are highlighted with arrows labeled "conducting channel / potential VT isthmus." Ablation lesion markers (red dots) are placed across these channels. (2) Beside the voltage map, show a schematic diagram of the reentrant VT circuit with entrance site (green arrow entering the channel), slow conduction zone through the isthmus (wavy red line), exit site (blue arrow leaving the scar), and wavefront propagating through normal myocardium back to the entrance. Label: dense scar, border zone, critical isthmus, entrance, exit, outer loop. Include a small color bar showing the voltage scale from 0 to 1.5 mV. </image>

Prevention of Sudden Cardiac Death

ICD Therapy

Secondary prevention with an ICD is a Class I indication in virtually all patients with prior sustained VT, ventricular fibrillation, or cardiac arrest, provided life expectancy exceeds one year. Primary prevention indications are discussed in the HFrEF lecture and include an ejection fraction of 35% or below after optimization of guideline-directed medical therapy, with specific considerations for laminopathy, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, Brugada syndrome, long QT syndrome, and catecholaminergic polymorphic VT per disease-specific guidelines. The wearable cardioverter-defibrillator serves as bridge therapy during the guideline-directed medical therapy optimization period, covering the 40-day post-MI window, the 90-day post-revascularization period, and the recovery phase from newly diagnosed dilated cardiomyopathy before a permanent ICD decision is made.

Antiarrhythmic Drug Therapy for VT Prevention

Amiodarone is the most effective antiarrhythmic drug for VT suppression and reduces ICD shocks, although it provides no mortality benefit, as demonstrated in the SCD-HeFT trial where the amiodarone arm performed equivalently to placebo for mortality. Sotalol is less effective than amiodarone and is used for VT suppression in ICD patients, with QTc monitoring required. Mexiletine, a Class IB sodium channel blocker, is used as an adjunct to amiodarone or sotalol for refractory VT and is also useful in long QT syndrome type 3. Quinidine is effective for Brugada syndrome through its Ito channel blocking properties, as well as for short QT syndrome and idiopathic ventricular fibrillation. Combination therapy approaches include amiodarone plus mexiletine and amiodarone plus ranolazine, though the latter has limited supporting data.

Key Clinical Pearls

• Hemodynamically stable wide complex tachycardia should be treated as VT until proven otherwise -- giving IV verapamil to scar-related VT can cause fatal cardiovascular collapse
• Procainamide is superior to amiodarone for hemodynamically stable monomorphic VT (PROCAMIO trial) and should be the first-line IV antiarrhythmic in this setting
• For TdP, the treatment triad is: IV magnesium + overdrive pacing/isoproterenol + discontinue all QT-prolonging agents; amiodarone should NOT be given for TdP (it prolongs QT further)
• Electrical storm refractory to amiodarone and esmolol should prompt consideration of stellate ganglion block or thoracic epidural -- these interventions are highly effective by interrupting sympathetic drive to the heart
• RVOT VT and fascicular VT occur in structurally normal hearts and are CURABLE by catheter ablation with >90-95% success rates -- always refer for EP evaluation
• VT in non-ischemic cardiomyopathy frequently has epicardial substrate -- plan for combined endo/epicardial ablation and counsel patients about the different risk profile of epicardial access

References

• Al-Khatib SM, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and Prevention of Sudden Cardiac Death. Circulation. 2018;138:e272-e391.
• Sapp JL, et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs (VANISH). NEJM. 2016;375:111-121.
• Ortiz M, et al. Randomized Comparison of Intravenous Procainamide vs. Intravenous Amiodarone for the Acute Treatment of Tolerated Wide QRS Tachycardia (PROCAMIO). Eur Heart J. 2017;38:1329-1335.
• Cronin EM, et al. 2019 HRS/EHRA/APHRS/LAHRS Expert Consensus Statement on Catheter Ablation of Ventricular Arrhythmias. Heart Rhythm. 2020;17:e2-e154.
• Priori SG, et al. 2015 ESC Guidelines for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Eur Heart J. 2015;36:2793-2867.

Read this lecture as Markdown